Karsiyaka Hendek, M.Olgun, E.Kisa, U.2025-01-212025-01-2120210045-04211834-7819https://doi.org/10.1111/adj.12815https://hdl.handle.net/20.500.12587/25598Background: The aim of study was to evaluate galectin-3 levels in gingival crevicular fluid (GCF) from periodontally healthy (H) patients and those with periodontitis (P), gingivitis (G) and the effect of initial periodontal treatment on GCF galectin-3 level. Methods: A total of 75 participants, 25 patients with periodontitis, 25 with gingivitis and 25 periodontally healthy subjects were included into the study. Patients with periodontal disease received initial periodontal treatment. GCF galectin-3 level was assessed at baseline and at the 6th-8th weeks after completion of periodontal treatment. GCF galectin-3 level was evaluated by enzyme-linked immunosorbent assay. Results: GCF galectin-3 level was the lowest in the H group (102.31[63.07] mu g/30 s), followed by the G group (241.45[145.89] mu g/30 s) and the highest in the P group (338.27[219.37] mu g/30 s). These differences were statistically significant between H and the other groups (P < 0.001). After initial periodontal treatment, GCF galectin-3 level significantly decreased in the G and P groups compared to baseline values (P < 0.01). Conclusion: The results of this study suggest that GCF galectin-3 level is a potential biomarker for the evaluation of gingival inflammation and initial periodontal treatment is effective in decreasing GCF galectin-3 level.eninfo:eu-repo/semantics/closedAccessGalectin-3; initial periodontal treatment; periodontal diseaseArticle66216917410.1111/adj.128152-s2.0-8510016873433378559Q2WOS:000608491300001Q3